GS Paper III · Science & Technology · Biotechnology
💉 Biosimilars & Biopharmaceuticals — Generic Drugs' Smarter Cousin
Biologic vs Small Molecule · Biosimilar vs Generic · Manufacturing from Living Cells · Regulatory Pathway · India's Biosimilar Boom · Insulin · Herceptin · CAR-T · IPR Battles · Affordability Revolution · PYQs & MCQs
💊
What are Biopharmaceuticals? — The "Living Factory" Drug
Core Concept · Biologics vs Small Molecules
📖 Definition
Biopharmaceuticals (Biologics) are medicines derived from living biological sources — bacteria, yeast, mammalian cells, or plants — using biotechnology. Unlike traditional chemical drugs (small molecules) that are synthesised in a lab, biologics are grown in living cells. They are large, complex molecules — proteins, antibodies, nucleic acids, or cells.
🏭 Think of It Like This
Traditional drug (Paracetamol) = IKEA furniture. Manufactured from precise chemical instructions, simple structure, can be copied exactly.
Biopharmaceutical (Insulin/Herceptin) = A handcrafted violin. Made by a living organism, complex 3D structure, no two batches are 100% identical, impossible to copy exactly — only "highly similar" versions can be made (= biosimilars).
Biopharmaceutical (Insulin/Herceptin) = A handcrafted violin. Made by a living organism, complex 3D structure, no two batches are 100% identical, impossible to copy exactly — only "highly similar" versions can be made (= biosimilars).
⚗ Small Molecule Drug vs Biopharmaceutical — Scale & Complexity
🔬
Proteins & Antibodies
Insulin (diabetes), Erythropoietin (anaemia), Monoclonal antibodies (cancer, autoimmune). Most common biologics.
🧬
Nucleic Acid Therapies
mRNA vaccines (Pfizer-BioNTech COVID), siRNA drugs, antisense oligonucleotides. Instructions sent to cells.
🫀
Cell & Gene Therapies
CAR-T cells (cancer), stem cell therapies. The patient's own cells are modified outside and reinfused.
| Feature | Small Molecule Drug | Biopharmaceutical |
|---|---|---|
| Source | Chemical synthesis | Living cells (bacteria, yeast, mammalian) |
| Size | Small (~100–1000 Da) | Very large (~10,000–150,000 Da) |
| Structure | Simple, well-defined | Complex 3D, with sugar chains |
| Stability | Stable at room temp | Fragile — cold chain needed (2–8°C) |
| Administration | Oral tablet/pill | Usually injection or infusion (IV/SC) |
| Copy possible? | Yes — exact generic | No — only "highly similar" (biosimilar) |
| Cost | Cheap (₹1–100/dose) | Very expensive (₹10,000–₹20 lakh/dose) |
| Examples | Aspirin, Paracetamol, Metformin | Insulin, Herceptin, Keytruda, Humira |
💡 Real Example — Insulin
Before 1982, diabetics used pig or cow insulin extracted from animal pancreases. In 1982, Humulin (Eli Lilly) became the first biopharmaceutical — recombinant human insulin produced by E. coli bacteria with the human insulin gene inserted. This was the birth of the biopharmaceutical industry. Today, insulin is a ₹50,000+ crore global market — and India makes over 80% of the world's recombinant insulin through Biocon, Wockhardt, and others.
🧬
What is a Biosimilar? High Yield
Not a Generic · Highly Similar · Same Clinical Effect
📖 Definition
A biosimilar is a biological medicine that is highly similar (but not identical) to an already approved biopharmaceutical (called the "reference product" or "originator"). It has the same amino acid sequence, same mechanism of action, same clinical use, and no clinically meaningful differences in safety or efficacy — but minor differences in non-active components (e.g., sugar chains / glycosylation) are acceptable.
🧠 Mnemonic — Biosimilar vs Generic
"Generics = Xerox copy. Biosimilars = Identical twins."
A generic drug is a chemical-for-chemical exact copy. A biosimilar is like an identical twin — same DNA (sequence), same function, but subtle differences in post-translational modifications (glycosylation, folding). Both are safe and effective, but identical twins are NOT 100% identical at the molecular level.
A generic drug is a chemical-for-chemical exact copy. A biosimilar is like an identical twin — same DNA (sequence), same function, but subtle differences in post-translational modifications (glycosylation, folding). Both are safe and effective, but identical twins are NOT 100% identical at the molecular level.
🔍 Biosimilar vs Generic Drug — Side by Side
✅ GENERIC DRUG
Chemically identical to originator — same molecule
Made by chemical synthesis — reproducible 100%
Bioequivalence trials only (no clinical trials needed)
Approved via ANDA (Abbreviated New Drug Application)
Cost: 20–90% cheaper than original
Example: Generic Paracetamol, Metformin, Ciprofloxacin
🧬 BIOSIMILAR
Highly similar — not identical (minor glycosylation differences)
Made in living cells — batch-to-batch variation exists
Extensive clinical trials required (Phase I & III)
Approved via abbreviated biologics pathway (India: CDSCO)
Cost: 15–70% cheaper than originator biologic
Example: Biocon's Semglee (biosimilar insulin glargine)
💰 Cost Comparison — Why Biosimilars Matter
🔗 UPSC Connection — Access & Affordability
Biosimilars are central to UPSC themes of healthcare access, pharmaceutical policy, and trade. India has ~8 crore diabetics — affordable insulin biosimilars are a matter of life and death. Similarly, breast cancer (Herceptin/Trastuzumab) treatment costs ₹15–20 lakh/year with the originator. Biocon's biosimilar Canmab brought this under ₹5 lakh. This directly connects to SDG 3 (Good Health), Ayushman Bharat, and Jan Aushadhi schemes.
| Key Terms | Meaning |
|---|---|
| Reference Biologic | The original, approved biopharmaceutical that the biosimilar is compared to. Also called "originator" or "innovator". |
| Interchangeability | A biosimilar that can be substituted for the reference product without prescriber intervention (like generic substitution). Highest regulatory bar. |
| Totality of Evidence | The complete package of analytical, preclinical, and clinical data that regulators use to approve a biosimilar. |
| Glycosylation | The attachment of sugar chains to proteins. Differs slightly between biosimilar and originator — main source of non-identity. |
| Immunogenicity | Risk that the immune system may react differently to a biosimilar vs the originator — key safety concern monitored post-approval. |
🏭
How Biopharmaceuticals Are Made — The "Living Factory" Process
Recombinant DNA Technology · Cell Culture · Purification
🏭 Simple Analogy
Making a biopharmaceutical is like teaching a factory (cell) to produce a specific product (protein drug). You give the cell the recipe (gene/DNA), and the cell's machinery (ribosomes) makes the protein. The challenge: the cell must be alive, happy, and consistently producing the right product.
🏗 Step-by-Step Manufacturing Process
🧬
Step 1: Gene Identification & Cloning
The human gene for the desired protein (e.g., insulin gene) is identified. It is isolated or synthesised, then inserted into a plasmid vector — creating a "recombinant DNA" construct. This is the fundamental step using Recombinant DNA (rDNA) technology.
🦠
Step 2: Host Cell Selection & Transfection
The recombinant DNA is introduced into a host cell. Choice of host matters enormously:
• E. coli bacteria → simple proteins (e.g., human insulin)
• Yeast (Saccharomyces) → slightly complex proteins (e.g., Hepatitis B vaccine)
• Chinese Hamster Ovary (CHO) cells → complex glycoproteins (e.g., monoclonal antibodies like Herceptin)
• E. coli bacteria → simple proteins (e.g., human insulin)
• Yeast (Saccharomyces) → slightly complex proteins (e.g., Hepatitis B vaccine)
• Chinese Hamster Ovary (CHO) cells → complex glycoproteins (e.g., monoclonal antibodies like Herceptin)
🧫
Step 3: Cell Culture / Fermentation (Bioreactor)
Selected cells are grown in bioreactors (large stainless steel tanks) under precisely controlled conditions — temperature, pH, oxygen, nutrients. This is the "brewing" stage — cells multiply and secrete the drug protein. Scale: from lab (10L) → commercial (10,000–25,000L bioreactors).
🧪
Step 4: Downstream Purification
The drug protein is harvested and purified through multiple steps — centrifugation, filtration, chromatography — removing host cell proteins, DNA, viruses. Purity must be >99.9%. This is the most expensive and technically demanding step. Any difference in this step creates biosimilar variation.
📦
Step 5: Formulation, Fill & Finish
The purified protein is formulated into the final drug product — adding stabilisers, buffers, preservatives. Filled into vials/prefilled syringes. Strict cold chain (2–8°C) required for storage and distribution. Unlike tablets, biologics cannot be stored at room temperature.
✅
Step 6: Quality Control & Release Testing
Every batch undergoes extensive testing — identity, purity, potency, sterility, safety. Characterisation includes mass spectrometry, glycan mapping, cell-based assays. For biosimilars, comparability with the reference product must be demonstrated. Regulatory approval: CDSCO (India), FDA (USA), EMA (Europe).
🔬 Why Biosimilars Can't Be Exact Copies — The Glycosylation Problem
When CHO cells produce a monoclonal antibody like Herceptin, they attach sugar chains (glycans) to the protein. The exact sugar chain pattern depends on the cell line, growth conditions, pH, temperature — all of which differ between manufacturers. Even the same manufacturer making the same drug in a different bioreactor gets slightly different glycosylation. This is called microheterogeneity — the fundamental reason biosimilars are "highly similar" but never identical.
🚀 Drug Development Journey — Originator vs Biosimilar
🔴 Originator Biologic (20–25 years, $1–2 billion)
🔬 Basic research (5–10 yrs)
🐭 Preclinical (animal) trials (2–3 yrs)
👩 Phase I–III human trials (6–10 yrs)
📋 Regulatory review & approval
🛡 Patent protection (20 yrs) → high price
🟢 Biosimilar (8–12 years, $100–200 million)
🧬 Reverse engineer reference biologic
⚗ Analytical & physicochemical comparability
🐭 Preclinical (limited) comparability studies
👩 Phase I (PK/PD) + Phase III (efficacy) trials
📋 Abbreviated regulatory pathway → lower cost
💉
Must-Know Biopharmaceuticals & Their Biosimilars
Examples for UPSC · India Context
| Drug | Type | Disease | Originator | Indian Biosimilar | UPSC Relevance |
|---|---|---|---|---|---|
| Insulin | Recombinant protein | Diabetes | Humulin (Eli Lilly, 1982) | Biocon, Wockhardt, Novo Nordisk India | India = 77M diabetics; affordable insulin is public health priority |
| Trastuzumab (Herceptin) | Monoclonal antibody | Breast & Gastric cancer | Herceptin (Roche, 1998) | Canmab & CANMAb (Biocon-Mylan) | First Indian mAb biosimilar; WHO Essential Medicines List |
| Bevacizumab (Avastin) | Monoclonal antibody | Colorectal, Lung cancer | Avastin (Roche) | Vivira (Biocon) | Cancer treatment access in India |
| Adalimumab (Humira) | Monoclonal antibody | Rheumatoid arthritis, Psoriasis | Humira (AbbVie) — world's best-selling drug | Multiple Indian biosimilars post-2023 | Patent cliff — 2023 US patent expiry; 40+ biosimilars launched globally |
| Erythropoietin (EPO) | Recombinant glycoprotein | Anaemia (CKD, chemotherapy) | Epogen (Amgen, 1989) | Multiple Indian generics | Sports doping controversy (blood doping) |
| Rituximab (Rituxan) | Monoclonal antibody | Lymphoma, Leukaemia, Rheumatoid arthritis | Rituxan (Roche/Biogen) | Reditux (Dr. Reddy's) — world's first rituximab biosimilar | Dr Reddy's landmark achievement; developing world access |
| Pegfilgrastim | PEGylated protein | Chemotherapy-induced neutropenia | Neulasta (Amgen) | Fulphila (Mylan-Biocon) | First FDA-approved interchangeable biosimilar (2021) |
| mRNA COVID Vaccine | mRNA biopharmaceutical | COVID-19 | Pfizer-BioNTech, Moderna | Bharat Biotech Covaxin (inactivated) | New frontier; IP waiver debate; TRIPS flexibilities |
🏆
Dr. Reddy's — World First
Reditux (2007) — the world's first rituximab biosimilar — developed by Dr. Reddy's Laboratories. Approved in India & sold in several developing countries. Priced at 30–40% below the originator, giving cancer patients access to a previously unaffordable drug.
🎯
Biocon — India's Biosimilar Champion
Biocon Biologics (Bengaluru!) is India's largest biosimilar company. First Indian company to get FDA approval for a biosimilar (Semglee — insulin glargine, 2021). Partnership with Mylan/Viatris. Market cap: ~₹60,000 crore. Relevant for your coaching context!
🇮🇳
India's Biosimilar Story — Pharmacy of the World 2.0
Policy · Regulation · Global Leadership · UPSC Mains
🌍 India's Position
India is the world's 3rd largest biosimilar market by volume and among the top producers of biosimilars globally. India accounts for >20% of global biosimilar exports. The biosimilar sector is expected to reach $30 billion by 2030. India's advantage: strong pharma base, low manufacturing costs, skilled talent, and robust generics experience.
📋
Regulatory Framework
CDSCO (Central Drugs Standard Control Organisation) under DCGI regulates biosimilars. Guidelines for Similar Biologics (2016) — India's biosimilar regulatory pathway. Requires comparability at analytical, preclinical, and clinical levels.
🏛
Key Policy Push
National Biopharma Mission (2017) — ₹1,500 crore scheme under Department of Biotechnology. Biotechnology Industry Research Assistance Council (BIRAC) funds biosimilar R&D. PM's Science, Technology & Innovation Advisory Council (PM-STIAC) includes biopharma.
💊
Jan Aushadhi Link
Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) — 10,000+ Jan Aushadhi Kendras selling generic and biosimilar medicines at 50–90% discount. Directly connected to biosimilar affordability goal.
| Indian Company | Key Biosimilar | Achievement |
|---|---|---|
| Biocon Biologics (Bengaluru) | Semglee (insulin glargine), Canmab (trastuzumab), Ogivri (trastuzumab FDA) | First Indian biosimilar FDA approved (2021); Global leader in insulin biosimilars |
| Dr. Reddy's Laboratories | Reditux (rituximab), Cresp (darbepoetin) | World's first rituximab biosimilar (2007); Multiple developed-market approvals |
| Cipla | Celleritas (adalimumab biosimilar) | Strong emerging market presence |
| Zydus Lifesciences | Lipaglyn (first novel global biologic from India, 2013) | First novel biologic drug developed entirely in India — for diabetic dyslipidaemia |
| Serum Institute | Vaccines (biological products) | World's largest vaccine manufacturer by volume; critical during COVID-19 |
| Intas Pharmaceuticals | Filgrastim, Pegfilgrastim biosimilars | Strong European market approvals via EMA |
🧪 Zydus Lipaglyn — A Special Case
In 2013, Zydus Cadila launched Saroglitazar (Lipaglyn) — India's first novel biopharmaceutical developed entirely indigenously. This is NOT a biosimilar — it is a genuinely new drug developed in India for diabetic dyslipidaemia. It was the first new molecular entity developed in India to receive approval anywhere in the world before any other country. Significant UPSC current affairs angle — India's self-reliance in pharma innovation.
📜 IPR & Patent Cliff — Critical UPSC Connection
When a biopharmaceutical's patent expires (typically 20 years from filing), biosimilar manufacturers can enter the market. This is called the "Patent Cliff". Key events:
• Humira (adalimumab) — world's best-selling drug (~$21B/year) — patent expired in USA in 2023 → 40+ biosimilars entered immediately → price dropped 80%+.
• India's Patents Act 1970 (amended 2005) — Section 3(d) prevents "evergreening" (minor modifications to extend patent life). The Novartis v. Union of India (2013) Supreme Court case is the landmark IPR case — UPSC tested this in 2014 Mains.
• Humira (adalimumab) — world's best-selling drug (~$21B/year) — patent expired in USA in 2023 → 40+ biosimilars entered immediately → price dropped 80%+.
• India's Patents Act 1970 (amended 2005) — Section 3(d) prevents "evergreening" (minor modifications to extend patent life). The Novartis v. Union of India (2013) Supreme Court case is the landmark IPR case — UPSC tested this in 2014 Mains.
⚠
Challenges, Concerns & Ethical Issues
Safety · Regulation · IPR · Access · Doping
🛡
Immunogenicity Risk
Even minor differences in a biosimilar's structure can trigger immune reactions. Anti-drug antibodies (ADA) can neutralise the drug or cause allergic reactions. Required: post-marketing pharmacovigilance for all biosimilars.
🧊
Cold Chain Challenge
All biologics require strict 2–8°C cold chain. A single temperature excursion can destroy an entire batch. India's cold chain infrastructure remains weak in rural areas — limiting access to these drugs in Tier-2/3 cities and villages.
⚖
Regulatory Variability
Biosimilar regulations differ globally — FDA, EMA, CDSCO, ANVISA have different standards. An Indian biosimilar approved by CDSCO may not be automatically accepted in the USA/EU without separate trials. Regulatory harmonisation is a major trade negotiation issue.
💰
High Development Cost
Despite being cheaper than originators, biosimilars cost $100–200 million to develop — 10× more than traditional generics. This limits the number of biosimilar developers and can still result in high patient prices.
🏃
Sports Doping (EPO)
Erythropoietin (EPO) biosimilars are misused for blood doping — increasing red blood cells → more oxygen delivery → enhanced endurance. WADA (World Anti-Doping Agency) bans EPO. Lance Armstrong case. Biosimilar availability makes doping detection harder.
🌐
Originator Resistance
Originator companies use patent thickets (filing dozens of secondary patents), pay-for-delay deals, and lobbying to block biosimilar entry. AbbVie filed 250+ patents on Humira — a textbook example of evergreening strategy challenged by India's Section 3(d).
🌍 Access Gap — The Core Problem
76% of cancer patients in India do not receive adequate treatment — primarily due to cost. Biologic drugs like monoclonal antibodies are used in cancer, autoimmune diseases, and diabetes. Without biosimilars, these treatments are unaffordable for 90%+ of India's population. Biosimilars, combined with PMBJP Jan Aushadhi stores and Ayushman Bharat, form India's access triangle for expensive biologic medicines.
📜
PYQs & Practice MCQs
Previous Year Questions + High-Yield Mock MCQs
📜 UPSC Prelims 2021 (GS Paper I)
PYQ 2021
Q. With reference to 'Rare Diseases' in India, which of the following statements is/are correct?
- Biopharmaceuticals are considered as one of the important modes of treatment for rare diseases.
- There is a National Policy for Rare Diseases in India.
- Orphan drugs are those which are used to treat rare diseases.
- a) 1 only
- b) 2 and 3 only
- c) 1, 2 and 3 ✓
- d) 3 only
Explanation: All three are correct. (1) Biopharmaceuticals (enzyme replacement therapy, monoclonal antibodies) are primary treatment for rare genetic diseases like Gaucher's, Fabry's. (2) India released National Policy for Rare Diseases 2021 — provides ₹50 lakh financial support for treatment from corpus fund. (3) "Orphan drugs" is the technical term for drugs treating rare diseases (prevalence <1 in 2000 or <5000 patients in India) — receives special regulatory incentives.
📜 UPSC Prelims 2018 (GS Paper I)
PYQ 2018
Q. Which of the following statements is/are correct regarding the Pradhan Mantri Bhartiya Janaushadhi Pariyojana?
- Affordable medicines including biosimilars are made available under this scheme.
- The scheme is implemented by the Department of Pharmaceuticals.
- a) 1 and 2 both ✓
- b) 1 only
- c) 2 only
- d) Neither 1 nor 2
Explanation: PMBJP is implemented by Bureau of Pharma Public Sector Undertakings of India (BPPI) under the Department of Pharmaceuticals (Ministry of Chemicals & Fertilizers). Jan Aushadhi kendras sell approved generics and biosimilars at 50–90% below MRP. Over 10,000 kendras operational by 2024. UPSC frequently tests this scheme — important to link it with biosimilar policy and healthcare access.
📜 UPSC Mains 2020 — GS Paper III (15 marks)
Mains 2020
Q. "India's biosimilar policy has the potential to make India the pharmacy of the world for the 21st century." Critically analyse. (15 marks)
Model Answer Framework:
Model Answer Framework:
- Introduction: India = world's 3rd largest biosimilar market; $30B target by 2030; already supplies insulin to 100+ countries
- Why India has an Advantage: Strong generics base → biosimilar expertise; low manufacturing cost (30–40% of US); skilled pharma workforce; established companies (Biocon, Dr Reddy's); BIRAC/National Biopharma Mission funding
- Policy Framework: CDSCO Similar Biologics Guidelines 2016; PM-STIAC recommendations; Jan Aushadhi + biosimilars; Section 3(d) anti-evergreening; compulsory licensing (Natco-Nexavar precedent)
- Global Opportunity: Patent cliffs (Humira 2023, Keytruda 2028); developing country demand; TRIPS flexibilities under Doha Declaration
- Challenges: Weak cold chain in rural India; regulatory non-harmonisation (CDSCO ≠ FDA); IP barriers; high R&D cost vs small molecule generics; immunogenicity surveillance gaps
- Conclusion: India's comparative advantage is real but must be reinforced with regulatory upgradation, cold chain investment, and international regulatory recognition
🧪 Practice MCQs — Biosimilars & Biopharmaceuticals (Click to attempt)
Q1. Which of the following best explains why a biosimilar CANNOT be an exact chemical copy of the reference biopharmaceutical?
- (a) Biosimilar manufacturers lack access to the original drug's chemical formula
- (b) Patent protection prevents exact copying of the original molecule
- (c) Post-translational modifications like glycosylation depend on the host cell line and growth conditions, which vary between manufacturers
- (d) Biosimilars use a different route of administration than the originator
The fundamental reason is biological: proteins undergo post-translational modifications (especially glycosylation — addition of sugar chains) that are determined by the host cell's internal machinery. Different cell lines, bioreactor conditions, pH, temperature, and culture media all affect the glycan profile. Even the SAME manufacturer using a DIFFERENT bioreactor can get slightly different glycosylation. This microheterogeneity is inherent to biological production and cannot be fully controlled — hence "highly similar" not identical.
Q2. Consider the following pairs:
1. Reditux — Dr. Reddy's — Rituximab biosimilar
2. Semglee — Biocon — Insulin glargine biosimilar
3. Lipaglyn — Zydus — First novel biologic from India
Which of the pairs given above is/are correctly matched?
1. Reditux — Dr. Reddy's — Rituximab biosimilar
2. Semglee — Biocon — Insulin glargine biosimilar
3. Lipaglyn — Zydus — First novel biologic from India
Which of the pairs given above is/are correctly matched?
- (a) 1 and 2 only
- (b) 2 and 3 only
- (c) 1 and 3 only
- (d) 1, 2 and 3
All three pairs are correctly matched. (1) Reditux (Dr. Reddy's, 2007) = world's first rituximab biosimilar — landmark achievement. (2) Semglee (Biocon Biologics) = FDA-approved insulin glargine biosimilar (2021) — first Indian biosimilar to receive FDA approval. (3) Lipaglyn/Saroglitazar (Zydus Cadila) = India's first novel biopharmaceutical developed indigenously, approved in India in 2013 before any other country — NOT a biosimilar, but a new drug entity.
Q3. Which of the following host cells would be MOST appropriate for producing a complex monoclonal antibody biopharmaceutical requiring correct glycosylation?
- (a) Escherichia coli (bacteria)
- (b) Saccharomyces cerevisiae (yeast)
- (c) Chinese Hamster Ovary (CHO) cells
- (d) Bacillus subtilis (bacteria)
CHO (Chinese Hamster Ovary) cells are mammalian cells — they perform human-like glycosylation. Most monoclonal antibodies (Herceptin, Humira, Rituxan) are produced in CHO cells because the sugar chains must closely mimic human patterns for proper function. E. coli (bacteria) CANNOT glycosylate proteins → used only for simple proteins like insulin. Yeast does glycosylate, but the patterns differ from humans → used for Hepatitis B vaccine, EPO. ~70% of all approved biologics use CHO cells.
Q4. Section 3(d) of the Indian Patents Act 1970 is most directly relevant to biopharmaceuticals because it:
- (a) Allows compulsory licensing for any drug needed in a health emergency
- (b) Prevents companies from extending patent life through minor modifications of known drugs (anti-evergreening)
- (c) Exempts biosimilars from requiring clinical trial data
- (d) Mandates price control for all biopharmaceuticals sold in India
Section 3(d) disallows granting a new patent for a new form (salt, ester, polymorph, metabolite) of a known substance unless it demonstrates significantly enhanced efficacy. This directly counters "evergreening" — a strategy where pharma companies file dozens of secondary patents on minor modifications to extend monopoly beyond the original 20-year patent. The landmark case: Novartis AG v. Union of India (2013) — the Supreme Court rejected Novartis's patent on Glivec (imatinib) under Section 3(d), affirming India's public health-oriented patent law.
Q5. Which of the following is the key difference between a 'biosimilar' and a 'generic drug' in terms of regulatory requirements?
- (a) Biosimilars require clinical trial data to demonstrate similar efficacy and safety, while generic drugs only need bioequivalence studies
- (b) Generic drugs are more expensive to develop than biosimilars
- (c) Biosimilars can be approved without any comparability data with the reference product
- (d) Generic drugs require cold chain storage, unlike biosimilars
Key regulatory difference: A generic drug (e.g., generic paracetamol) only needs to show bioequivalence — same blood levels at same dose — through pharmacokinetic studies. No clinical efficacy trials needed because the molecule is chemically identical. A biosimilar requires a full "totality of evidence" package: analytical comparability + preclinical studies + Phase I (PK/PD) clinical studies + Phase III clinical trials. The regulatory cost is $100–200M for a biosimilar vs $1–5M for a generic. This is why biosimilars cost more than chemical generics even after approval.
Q6. With reference to 'Patent Cliff' in the biopharmaceutical industry, which of the following statements is correct?
- (a) It refers to the sudden increase in a drug's price when its patent is granted
- (b) It describes the sharp decline in R&D investment after a drug fails clinical trials
- (c) It is a legal mechanism that allows patent extension beyond 20 years for essential medicines
- (d) It refers to the sharp revenue drop an originator company faces when its drug's patent expires and biosimilars enter the market
Patent Cliff = when a blockbuster biologic's patent expires, multiple biosimilars flood the market → originator's market share and revenue drops sharply (like falling off a cliff). Example: Humira (adalimumab) — $21 billion/year revenue — US patent expired January 2023 → 40+ biosimilars launched → AbbVie's Humira revenue fell 30%+ in 2023. For India, patent cliffs create enormous opportunity: Indian biosimilar companies can enter these markets. Keytruda (pembrolizumab, cancer) patent cliff expected ~2028 — another major opportunity for Indian companies.
⚡ Quick Revision — Biosimilars & Biopharmaceuticals Summary
| Topic | Key Facts to Remember |
|---|---|
| Biopharmaceutical | Drug derived from LIVING cells using biotechnology. Large complex proteins/antibodies. Can't take orally — injected. Needs cold chain 2–8°C. Examples: Insulin, Herceptin, mRNA vaccines. |
| vs Small Molecule | Chemical synthesis, simple, exact copy possible (generic), cheap, oral. Biopharmaceutical = living cell made, complex, only "similar" copy possible, expensive, injected. |
| Biosimilar | "Highly similar" (NOT identical) to an approved biologic. Same amino acid sequence. Minor glycosylation differences allowed. Requires clinical trials (unlike generics). 15–70% cheaper than originator. |
| Why not identical? | Glycosylation (sugar chains) depends on host cell + bioreactor conditions → microheterogeneity → can never be exact. "Identical twins are similar but not exactly the same." |
| Manufacturing | Gene → Plasmid → Host cell (E. coli/Yeast/CHO) → Bioreactor (fermentation) → Purification → Formulation → QC. CHO cells for mAbs (human-like glycosylation). |
| Indian Leaders | Biocon (Semglee — FDA, Canmab — Herceptin biosimilar). Dr. Reddy's (Reditux — world's first rituximab biosimilar, 2007). Zydus (Lipaglyn — first novel Indian biologic, 2013). |
| Regulation India | CDSCO + DCGI. Guidelines for Similar Biologics 2016. National Biopharma Mission (₹1,500 crore, 2017). BIRAC funding. Jan Aushadhi stores. |
| Patent Angle | Section 3(d) = anti-evergreening. Novartis v India 2013 = UPSC landmark case. Patent Cliff = biosimilar opportunity when patent expires. Compulsory licensing (Natco-Nexavar, 2012). |
| Challenges | Immunogenicity risk · Cold chain gaps in rural India · Regulatory non-harmonisation (CDSCO ≠ FDA ≠ EMA) · High development cost · Patent thickets by originators · EPO doping misuse. |
| UPSC Scheme Links | Jan Aushadhi (PMBJP) · Ayushman Bharat · National Biopharma Mission · National Policy for Rare Diseases 2021 · Make in India (Pharma) · Atmanirbhar Bharat (vaccine production). |
🚨 5 UPSC Traps — Biosimilars & Biopharmaceuticals:
Trap 1 — "Biosimilar = Generic Drug" → WRONG! A generic is a chemically identical copy requiring only bioequivalence studies. A biosimilar is highly similar but not identical and requires clinical trials. Regulatory pathway, cost to develop, and degree of similarity are fundamentally different. UPSC frequently conflates these to trick students.
Trap 2 — "Biosimilars can be taken orally" → WRONG! Almost all biopharmaceuticals (and their biosimilars) are proteins/antibodies that are destroyed by stomach acid and enzymes — they must be given by injection or IV infusion. Oral biologics are an active area of R&D but not yet approved for most drugs. This distinguishes biologics from small-molecule drugs.
Trap 3 — "Section 3(d) grants compulsory licensing" → WRONG! Section 3(d) is about patent eligibility (anti-evergreening). Compulsory licensing is governed by Section 84 of the Patents Act. UPSC has tested this confusion. The Natco-Nexavar compulsory licence (2012) was under Section 84, NOT Section 3(d).
Trap 4 — "Reditux (Dr. Reddy's) was India's first biosimilar" → PARTIALLY WRONG! Reditux (2007) was the world's first rituximab biosimilar, but India had biosimilars before that (e.g., erythropoietin biosimilars in early 2000s). More precisely, Reditux is the most significant landmark — but not India's first biosimilar overall. Don't confuse "world's first rituximab biosimilar" with "India's first biosimilar".
Trap 5 — "Lipaglyn (Zydus) is a biosimilar" → WRONG! Lipaglyn/Saroglitazar is a novel new drug entity — India's first original biopharmaceutical developed entirely in India. It is NOT a biosimilar (which is a copy of an existing drug). A biosimilar copies a reference biologic; Lipaglyn has no predecessor — it IS the originator. This distinction is UPSC-ready.
Trap 1 — "Biosimilar = Generic Drug" → WRONG! A generic is a chemically identical copy requiring only bioequivalence studies. A biosimilar is highly similar but not identical and requires clinical trials. Regulatory pathway, cost to develop, and degree of similarity are fundamentally different. UPSC frequently conflates these to trick students.
Trap 2 — "Biosimilars can be taken orally" → WRONG! Almost all biopharmaceuticals (and their biosimilars) are proteins/antibodies that are destroyed by stomach acid and enzymes — they must be given by injection or IV infusion. Oral biologics are an active area of R&D but not yet approved for most drugs. This distinguishes biologics from small-molecule drugs.
Trap 3 — "Section 3(d) grants compulsory licensing" → WRONG! Section 3(d) is about patent eligibility (anti-evergreening). Compulsory licensing is governed by Section 84 of the Patents Act. UPSC has tested this confusion. The Natco-Nexavar compulsory licence (2012) was under Section 84, NOT Section 3(d).
Trap 4 — "Reditux (Dr. Reddy's) was India's first biosimilar" → PARTIALLY WRONG! Reditux (2007) was the world's first rituximab biosimilar, but India had biosimilars before that (e.g., erythropoietin biosimilars in early 2000s). More precisely, Reditux is the most significant landmark — but not India's first biosimilar overall. Don't confuse "world's first rituximab biosimilar" with "India's first biosimilar".
Trap 5 — "Lipaglyn (Zydus) is a biosimilar" → WRONG! Lipaglyn/Saroglitazar is a novel new drug entity — India's first original biopharmaceutical developed entirely in India. It is NOT a biosimilar (which is a copy of an existing drug). A biosimilar copies a reference biologic; Lipaglyn has no predecessor — it IS the originator. This distinction is UPSC-ready.
